47931-85-1
Chemical Structure
Calcitonin (salmon)
Synonym(s): Salmon calcitonin
- CAS No.: 47931-85-1
- Formula:C145H240N44O48S2
- Molecular Weight:3431.85
SMILES: OC(C=C1)=CC=C1C[C@H](NC([C@H]([C@H](O)C)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC(CNC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H]2NC([C@](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC2)N)=O)CO)=O)CC(N)=O)=O)CC(C)C)=O)CO)=O)([H])[C@H](O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CN=CN3)=O)=O)=O)=O)=O)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CO)C(NCC(N[C@@H]([C@H](O)C)C(N5[C@@H](CCC5)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Calcitonin (salmon) (Salmon calcitonin) is a calcitonin receptor agonist and osteoclast inhibitor. Calcitonin (salmon) activates the calcitonin receptor/Cyclic AMP (cAMP) (HY-B1511) signaling pathway, binds to the amylin receptor (rat Kd = 30 pmol/L), inhibits osteoclast motility and bone resorption, and lowers plasma calcium. Calcitonin (salmon) induces proteoglycan and type II collagen synthesis, activates skeletal muscle glycogen phosphorylase and adenylate cyclase, stimulates glycogenolysis and increases plasma lactic acid (Lactic acid) (HY-B2227)/glucose (D-Glucose) (HY-B0389), inhibits insulin and gastric acid secretion and gastric emptying, and stimulates renin secretion. Calcitonin (salmon) relieves bone pain and produces antidepressant-like effects by inhibiting hippocampal p38 MAPK/JNK. Calcitonin (salmon) can be used in research on osteoporosis, osteoarthritis, Paget's disease, glucocorticoid-induced osteopenia, hyperglycemia, and depression[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Calcitonin (salmon) | 99.96% | Calcitonin (salmon) (Salmon calcitonin) is a calcitonin receptor agonist and osteoclast inhibitor. Calcitonin (salmon) activates the calcitonin receptor/Cyclic AMP (cAMP) (HY-B1511) signaling pathway, binds to the amylin receptor (rat Kd = 30 pmol/L), inhibits osteoclast motility and bone resorption, and lowers plasma calcium. Calcitonin (salmon) induces proteoglycan and type II collagen synthesis, activates skeletal muscle glycogen phosphorylase and adenylate cyclase, stimulates glycogenolysis and increases plasma lactic acid (Lactic acid) (HY-B2227)/glucose (D-Glucose) (HY-B0389), inhibits insulin and gastric acid secretion and gastric emptying, and stimulates renin secretion. Calcitonin (salmon) relieves bone pain and produces antidepressant-like effects by inhibiting hippocampal p38 MAPK/JNK. Calcitonin (salmon) can be used in research on osteoporosis, osteoarthritis, Paget's disease, glucocorticoid-induced osteopenia, hyperglycemia, and depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.96
HY-P1463Calcitonin, eel -
Similarity Score 0.93
HY-P10237Calcitonin (chicken) -
Similarity Score 0.90
HY-P0007Elcatonin -
Similarity Score 0.89
HY-P11610KBP-089 -
Similarity Score 0.86
HY-P11320Davalintide -
Similarity Score 0.83
HY-P1782Calcitonin (8-32), salmon -
Similarity Score 0.81
HY-P4973Calcitonin (rat) -
Similarity Score 0.80
HY-P1393AC 187 -
Similarity Score 0.80
HY-P11665Batelintide -
Explore the MedChemAI to find more analogs
References
- [1]. Glowka E, et al. Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles. Journal of microencapsulation. 2010;27(1):25-36.
- [2]. Ray MV, et al. Production of salmon calcitonin by direct expression of a glycine-extended precursor in Escherichia coli. Protein expression and purification. 2002 Nov;26(2):249-59.
- [3]. Trier S, et al. Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2015 Oct;96:329-37.
- [4]. Sondergaard BC, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC musculoskeletal disorders. 2010 Apr 05;11:62.
- [5]. Young AA, et al. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism: clinical and experimental. 1995 Dec;44(12):1581-9.
- [6]. Zhu W, et al. (2023) Chronic salmon calcitonin exerts an antidepressant effect via modulating the p38 MAPK signaling pathway. Front. Mol. Neurosci. 16:1071327.
- [7]. Mahesh Kumar T, et al. Pulmonary absorption enhancement of salmon calcitonin. Journal of drug targeting. 2004 Apr;12(3):135-44.
- [8]. Gaggi R, et al. Salmon calcitonin induced head twitch in the rat. Japanese journal of pharmacology. 1988 May;47(1):87-90.
- [9]. Furuichi H, et al. Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biological & pharmaceutical bulletin. 2000 Aug;23(8):946-51.
